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Abstract: The discovery of endogenous peptide ligands for morphine binding sites occurred in
parallel with the identification of three subclasses of opioid receptor (OR), traditionally designated as
µ, δ, and κ, along with the more recently defined opioid-receptor-like (ORL1) receptor. Early efforts
in opioid receptor radiochemistry focused on the structure of the prototype agonist ligand, morphine,
although N-[methyl-11C]morphine, -codeine and -heroin did not show significant binding in vivo.
[11C]Diprenorphine ([11C]DPN), an orvinol type, non-selective OR antagonist ligand, was among the
first successful PET tracers for molecular brain imaging, but has been largely supplanted in research
studies by the µ-preferring agonist [11C]carfentanil ([11C]Caf). These two tracers have the property
of being displaceable by endogenous opioid peptides in living brain, thus potentially serving in a
competition-binding model. Indeed, many clinical PET studies with [11C]DPN or [11C]Caf affirm the
release of endogenous opioids in response to painful stimuli. Numerous other PET studies implicate
µ-OR signaling in aspects of human personality and vulnerability to drug dependence, but there have
been very few clinical PET studies of µORs in neurological disorders. Tracers based on naltrindole, a
non-peptide antagonist of the δ-preferring endogenous opioid enkephalin, have been used in PET
studies of δORs, and [11C]GR103545 is validated for studies of κORs. Structures such as [11C]NOP-1A
show selective binding at ORL-1 receptors in living brain. However, there is scant documentation of
δ-, κ-, or ORL1 receptors in healthy human brain or in neurological and psychiatric disorders; here,
clinical PET research must catch up with recent progress in radiopharmaceutical chemistry.
Keywords: opioid receptors; positron emission tomography; radiotracers; µOR-, δOR-, κOR- and
ORL1-ligands; epilepsy; movement disorders; pain; drug dependence
1. Introduction
The analgesic and soporific properties of opium have been known since antiquity, perhaps first
attested in the detached reveries of Homer’s Lotophagi. The sinister side of opium dreams is depicted
in Tennyson’s version of that story, and more distinctly in the memoires of Thomas de Quincy, who
may have had the distinction of establishing a genre of literature, the addiction diary. A key active
constituent of the sap of Papaver somniferum was first isolated in 1804 by the apothecary Friedrich
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Wilhelm Sertürner, who named it morphium, later morphine (1). Chemists identified its elemental
composition in the 19th century, and efforts to determine its structure were rewarded in 1925, when
Gulland and Robinson [1] recommended a structure consistent with the characteristics of morphine
and codeine and their degradation products. Subsequent investigations confirmed the correctness
of the analytically deduced structure of morphine, culminating in its total synthesis, achieved in the
1950s by Gates and Tschudi [2,3]. The absolute stereochemistry of morphine’s five chiral carbons (5, 6,
9, 13 and 14) was reported by Bentley and Cardwell [4] in 1955, and the first practically realizable
morphine total synthesis with reasonable yields was reported by Rice in 1980 [5]. To this day, it is more
economical to allow the poppy plant to do the main work of morphine (1) synthesis, although chemists
have since produced so many structural variants that one might consider opioid pharmacology to be a
discipline in its own right. There have been several reviews of opioid receptor imaging in the past
decade [6–8], but we now present a comprehensive update on the the main classes of opioid receptor
(OR) ligands used for positron emission tomography (PET), and review clinical findings with this
technology. Relevant chemical structures of endogenous opioid peptides and representative small
molecule opioid receptor ligands are depicted in Figure 1.
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Figure 1. Chemical structures of endogenous opioid peptides and selected opioid receptor ligands. 
The modern era of opioid pharmacology began with the identification of an opioid binding site 
in brain tissue in studies with tritiated naloxone [9]. Soon thereafter, opioid peptides were isolated 
from pig brain [10], which famously involved whisky as an emolument for the slaughterhouse 
workers. The pentapeptides Met5-enkephalin (2) and Leu5-enkephalin (3) both had morphine-like 
effects in inhibiting the electrically stimulated contraction of the vas deferens, with the latter 
compound being somewhat less potent. The enkephalins were most abundant in striatum and 
hypothalamus of rat, guinea pig and calf, and Met5-enkephalin (2) was generally 3–6 times more 
abundant than Leu5-enkephalin (3) [11,12]. An additional higher molecular weight opioid 
(β-endorphin) isolated and sequenced from camel pituitary extracts proved to be a 31 amino acid 
polypeptide possessing homology with Met5-enkephalin (2) [13]. A trypsin-sensitive opioid activity 
(dynorphin-A) isolated from pituitary is a 17 amino acid polypeptide possessing N-terminal 
homology with Leu5-enkephalin (3), with the shorter peptide dynorphin-B [1-13] having almost 
1000-fold higher potency than Leu5-enkephalin (3) in the guinea pig ileum muscle preparation [14]. 
Soon after these discoveries, bovine DNA sequences were cloned for the β-endorphin precursor 
corticotropin-β-lipotropin [15], the Met5/Leu5-enkephalin (2, 3) precursor preproenkephalin-A [16] 
(which proved to contain four copies of Met5-enkephalin (2) and one copy of Leu5-enkephalin (3), 
consistent with the ratio of their tissue concentrations), and the closely related preproenkephalin-B 
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The modern era of o ioi harmacology began with the identification of an opioid binding
site in brain tissue in studies with tritiated naloxone [9]. Soon thereafter, opioid peptides were
isolated from pig brain [10], which famously involved whisky as an emolument for the slaughterhouse
workers. The pentapeptides Met5-enkephalin (2) and Leu5-enkephalin (3) both had morphine-like
effects in inhibiting the electrically stimulated contraction of the vas deferens, with the latter compound
being somewhat less potent. The enkephalins were most abundant in striatum and hypothalamus
of rat, guinea pig and calf, and Met5-enkephalin (2) was generally 3–6 times more abundant than
Leu5-enkephalin (3) [11,12]. An additional higher molecular weight opioid (β-endorphin) isolated and
sequenced from camel pituitary extracts proved to be a 31 amino acid polypeptide possessing homology
with Met5-enkephalin (2) [13]. A trypsin-sensitive opioid activity (dynorphin-A) isolated from pituitary
is a 17 amino acid polypeptide possessing N-terminal homology with Leu5-enkephalin (3), with the
shorter peptide dynorphin-B [1-13] having almost 1000-fold higher potency than Leu5-enkephalin (3) in
the gui ea pig il um muscle preparation [14]. Soon aft r th s discoveries, bovine DNA sequence were
cloned f r the β-end rphi precursor corticotropin-β-lipotropin [15], the Met5/L u5-enkephalin (2, 3)
precursor eproenkeph lin-A [16] (which proved to contain four copies of Met5-enkephalin (2) and
one copy of Leu5-enkephalin (3), consistent with the ratio of their tissue concentrations), and the closely
related preproenkephalin-B [17]. Other researchers cloned porcine preprodynorphin, the precursor for
dynorphin A [1-17], dynorphin-A [1-8], dynorphin B [1-13], and other opioid peptides [18].
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It was soon apparent that the endogenous opioid peptides bound to at least three distinct sites
in the brain and peripheral tissues, known as µ-, δ-, and κORs. For a time, the orphaned σ receptors
were thought to comprise another type of OR [20], due to the analgesic (and hallucinogenic) action
of pentazocine at κORs in brain. However, binding of σOR ligands is not displacable by the opioid
antagonist naloxone, nor do σORs bind opioid peptides with high affinity, such that the σ- receptor
is now recognized as a pharmacological class in its own right. The µOR gene has at least 14 exons
that can give rise to diverse splice variants, and at least three pharmacologically distinct subtypes are
recognized: µ1, µ2 and µ3. Displacement studies in vitro and in vivo with the µ-selective competitive
antagonist cyprodime (6) and the µ1-specific competitor naloxonazine (7) showed that [11C]carfentanil
([11C]Caf, 8) binds predominantly to the µ1 subtype [21]. The µ3 subtype is alkaloid sensitive and
opioid peptide insensitive; it couples to nitric oxide generation, and, extraordinarily, its endogenous
agonist in amygdala seems to be morphine (1) [22]. There is also an opioid receptor-like receptor
1 (ORL1), which is activated by the 17 amino acid polypeptide known as nociceptin/ orphanin FQ
(N/OFQ) [23].
Opioid signaling has an important function in the modulation of pain processing at the spinal
level. ORs synthetized in the dorsal root ganglion are transported to peripheral nerve endings and to
the superficial layers of the spinal cord dorsal horn. In the dorsal horn, µORs are the most densely
expressed subtype, followed by δ-, and κORs. Over 70% of the ORs there are located on the central
terminals of small-diameter (mostly C and A-delta fibres) primary afferent neurons. A main mechanism
of opioid analgesia lies in the activation of presynaptic µORs in the spinal cord, leading to decreased
release of excitatory transmitters and nociceptive transmission. Unforunately, PET methods do not
suffice for detecting ORs in the human spinal cord.
Figure 2 shows PET images of the distributions in human telencephalon of binding sites for the four
main classes of ORs, µ, δ, κ, and ORL1. The pattern of µORs in Figure 2A encompasses the telencephalic
pain pathway of limbic brain regions. Supraspinal µORs in the nucleus accumbens and amygdala
have a role in the analgesic and reinforcing properties of opioids. The thalamus, especially the medial
structures, relay nociceptive spinothalamic input from the spinal cord to higher structures. µORs also
have a prominent distribution in the brainstem, with high density in several structures associated with
analgesia, such as the periaqueductal gray, rostroventral medulla, the reticular formation, and locus
coeruleus [24–26]. From these structures, efferent outflow descends to the spinal cord where it acts to
inhibit nociceptive transmission in afferent fibres. µORs are also abundant in the hypothalamus, where
they might affect hormonal regulation. Receptors in the medullary vagal complex, area postrema, and
nucleus tractus solitarius, can mediate endocrine actions and nausea.
As seen in Figure 2B, the δOR has high expression in the cerebral cortex, nucleus accumbens, and
the caudate putamen. This receptor is involved in analgesic activity at both spinal and supraspinal sites.
Similarly as µORs, agonists of central δORs contribute to respiratory depression, whereas receptors
in the gut mediate constipation, an important side effect of morphine. The δORs receptors localize
presynaptically where they inhibit the release of excitatory neurotransmitters [27]. Despite these
properties, δ-selective drugs have not yet found clinical application.
The κORs have wide expression in rat brain, with highest levels in the ventral tegmental area,
substantia nigra, nucleus accumbens, caudate putamen, claustrum, endoperiform nucleus, various
hypothalamic nuclei, and the amygdala [28]. A similar expression profile occurs in the human
brain [29,30], as seen in Figure 2C. Activation of κORs does not produce respiratory depression, but
typical adverse effects include sedation and dysphoria, limiting the clinical use of κOR targeting
drugs [27]. Despite generally dysphoric effects in humans, the κOR agonist Salvinorin-A, which is
obtained from the leaves of Salvia divinorum, finds a niche market in the drug subculture for those
seeking to briefly experience a dissociative state.
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high binding in the insular cortex, lateral frontal cortex and amygdala; (D) the NOP antagonist 
[11C]NOP-1A, which binds abundantly throughout the brain. Binding sites of μ-, κ- and NOP-OR 
ligands are expressed as binding potential relative to the cerebellum (BPND), whereas binding of the 
δ-ligand (which has no non-binding reference region) is expressed as net influx (Ki,) in units of 
perfusion (mL cm−3 min−1). The color scale in the lower right indicates (for A, C, and D) BPND ranging 
from 0 to 2, or (B) Ki ranging from 0–0.1 mL cm−3 min−1 
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Figure 2. Human brain opioid receptor PET images in coronal (upper row) and axial (lower row)
planes. Modified and reproduced with permission from Peciña et al. [19]. From left to right, we see (A)
the µOR agonist [11C]carfentanil, binding most abundantly in the caudate nucleus, anterior cingulate
cortex, thalamus, and pituitary gland; (B) the δOR antagonist N1′-([11C]methyl)natrindole, which has
diffuse binding throughout neocortex; (C) the κOR antagonist [11C]LY2795050, which has high binding
in the insular cortex, lateral frontal cortex and amygdala; (D) the NOP antagonist [11C]NOP-1A, which
binds abundantly throughout the brain. Binding sites of µ-, κ- and NOP-OR ligands are expressed as
binding potential relative to the cerebellum (BPND), whereas binding of the δ-ligand (which has no
non-binding reference region) is expressed as net influx (Ki,) in units of perfusion (mL cm−3 min−1).
The color scale in the lower right indicates (for A, C, and D) BPND ranging from 0 to 2, or (B) Ki ranging
from 0–0.1 mL cm−3 min−1
Figure 2D shows a widespread and abundant expression of NOP binding sites in human brain.
Agonists of the NOP receptor, unlike µOR agonists, are devoid of reinforcing or motivational properties,
but are implicated in homeostatic functions such as feeding and body weight, as well as anxiety, stress,
and alcohol dependence [31].
2. Radiotracers for the PET Imaging of ORs
2.1. µOR Ligands and Non-Selective Ligands
The era of OR PET imaging was preceded by a phase of studies ex vivo with tritiated ligands
such as the antagonist [3H]diprenorphine ([3H]DPN), which accumulated in striatum, locus coeruleus,
substantia nigra pars compacta, and substantia gelatinosa of the living rat [32]. A similar pattern was
revealed with the antagoninst [3H]naloxone, which showed sodium-dependent saturable binding ex
vivo, with a Bmax close to that seen in vitro [33]. In contrast, the agonist [3H]Foxy bound with low
nM affinity at µORs in vitro, but failed to accumulate in brain of living rats, a property which was
attributed to the presence of high sodium in the living organism. The presence of sodium in the biding
medium enhanced antagonist binding in vitro but decreases agonist binding [34]. However, addition of
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Na+ to the incubation medium had little effect on the affinity of the morphiceptin analog µOR agonist
Tyr-Pro-(NMe)Phe-D-Pro-NH2 in vitro ([3H]PL017) [35]. Unpredictable sensitivity of binding to the
presence of sodium in the medium seems mainly to be a property of agonist ligands.
OR PET imaging began with the introduction of 3-O-acetyl-[18F]cyclofoxy (3-O-Ac-[18F]FcyF),
(10). 3-O-Ac-[18F]FcyF (10, Figure 3) is an opioid antagonist radiotracer, which was prepared
from 3-O-acetyl-6α-naltrexol triflate via direct nucleophilic substitution with tetraethylammonium
[18F]fluoride in anhydrous acetonitrile at 80 ◦C for 15 min [36,37]. Based on displacement studies with
CyF, binding of 3-O-Ac-[18F]FcyF (10) is likely to reveal the composite of µ- and κOR binding [38],
despite the qualitatively µOR-like binding pattern reported in living baboon brain examined with
3-O-Ac-[18F]FcyF (10) [36], and the pattern of [3H]cyclofoxy retention in rat brain analysed ex vivo [39].
However, in a rat study, the increased [3H]cyclofoxy binding provoked by chronic treatment with
morphine (1) could be attributed to upregulation of µOR sites [40]. Saturation binding PET studies
with [18F]FcyF (11) in awake rat indicated a single binding site with apparent affinity of 2 nM and Bmax
ranging from 15 pmol/g in white matter to 74 pmol/g in striatum; these results matched closely the
corresponding results obtained in vitro [41].
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[11C]L-α-acetylmethadol ([11C]LAAM, 13) had moderate uptake in brain of mice, but its specific 
binding was not reported [44]. These observations are a case in point supporting the generalization 
that effective pharmaceuticals do not necessary make good ligands for molecular imaging of their 
targets. 
The displaceability of OR ligands by competitors in vivo is a complex matter, and one 
increasingly relevant given the current opioid abuse crisis in some countries. Whereas antagonists 
such as naloxone are effective in rescuing addicts from death by overdose, naloxone also finds 
experimental use in molecular imaging studies to confirm binding of PET tracers to ORs. Thus, the 
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PET studies with N-[methyl-11C]-labelled morphine, codeine, heroin and pethidine indicated
distinct differences in uptake and kinetics in rhesus brain [42], all seemingly in relation to lipophilicity of
the various drugs. A more detailed kinetics analysis of N-[methyl-11C]pethidine (12) in brain of rhesus
monkey indicated a very low binding potential [43]. The methadone analogue [11C]L-α-acetylmethadol
([11C]LAAM, 13) had moderate uptake in brain of mice, but its specific binding was not reported [44].
These observations are a case in point supporting the generalization that effective pharmaceuticals do
not necessary make good ligands for molecular imaging of their targets.
The displaceability of OR ligands by competitors in vivo is a complex matter, and one increasingly
relevant given the current opioid abuse crisis in some countries. Whereas antagonists such as naloxone
are effective in rescuing addicts from death by overdose, naloxone also finds experimental use in
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molecular imaging studies to confirm binding of PET tracers to ORs. Thus, the BPND of [11C]Caf (8)
to µORs in human brain, which ranged from 1.0 in cerebellum to 2.7 in caudate nucleus, was nearly
completely displaced throughout in brain by a 50-mg dose of naltrexone (NTX, 5) [45], closely matching
the dose used for resuce from opioid agonist overdose. In humans, intranasal naloxone administration
caused a rapid displacement of [11C]Caf (8), in accordance with the rapid response seen in treatment
for overdose [46].
Buprenorphine (BPN) [47–49] is a narcotic analgesic used since the 1970s in the low dose
management of post-operative pain. Since 2002, BPN has approval in the United States at higher dose
or in combination with naloxone (Suboxone®) for substitution therapy in the management of opiate
addiction. BPN contains the same 6,14-ethenomorphinan skeleton as diprenorphine (DPN), and both
compounds have an N17-cyclopropylmethyl substituent, although BPN contains a tert-butyl group in
position-20 instead of methyl. Interestingly, BPN has a completely different pharmacological profile
than DPN. Whereas DPN is a mixed antagonist, BPN is a partial µOR agonist and κOR antagonist, and
displays some affinity for the NOP receptor [50] (Table 1).
Table 1. Binding profile of selected ligands at the human opioid receptors [51] .
Ki [nM] CompoundLigand
µ-OR δ-OR κ-OR NOP Action Class Ref.
Met5-enkephalin 261 9.9 - - agonist δOR EOP Stefanucci [52]
Leu5-enkephalin 513 10.7 - - agonist δOR EOP Stefanucci [52]
β-Endorphin 2.1 2.4 96 - agonist µOR, κOR EOP Corbett [53]
Dinorphin A 1.6 1.25 0.05 386 agonist κOR EOP Zhang [54]
Nociceptin 437 2846 147 0.08 agonist EOP Cami-Cobeci [50]
Morphine 2.06 >10,000 134 >10,000 agonist µOR EM Valenzano [55]
Oxycodone 16 7680 43,000 - agonist µOR EM Miyazaki [56]
Naltrexone 0.62 12.3 1.88 - antagonist EM Zheng [57]
Carfentanil 0.07 - - - agonist µOR 4-AP Henriksen [58]
Carfentanila 0.051 4.7 13 - agonist µOR 4-AP Frost [59]
Carfentanilb 0.024 3.28 43.1 - agonist µOR 4-AP Cometta [60]
Cyclofoxya 2.62 89 9.3 - antagonist µOR, κOR EM Rothman [38]
DPN 0.07 0.23 0.02 - antagonist orvinol Raynor [61]
BPN 1.5 6.1 2.5 77.4 partial µOR agonist, κOR antagonist orvinol Cami-Cobeci [50]
PEO 0.18 5.1 0.12 - full agonist orvinol Marton [62]
FE-DPN 0.24 8.00 0.20 - antagonist orvinol Schoultz [63]
FE-BPN 0.24 2.10 0.12 - mixed agonist/antagonist orvinol Schoultz [63]
FE-PEO 0.10 0.49 0.08 - full agonist orvinol Schoultz [63]
NTIb 3.8 0.03 332 - antagonist δOR EM Portoghese [64]
MeNTIb 14 0.02 65 - antagonist δOR EM Portoghese [64]
GR103545 16.2 536 0.02 - agonist κOR ArAP Schoultz [65]
LY2459989a 7.68 91.3 0.18 - antagonist κOR APPB Zheng [66]
LY2795050 25.8 153 0.72 - antagonist κOR APPB Zheng [57]
FEKAP 7.4 139 0.43 - agonist κOR ArAP Li [67]
EKAP 8.6 386 0.28 - agonist ArAP Li [68]
MeJDTic 8.88 118 1.01 - antagonist κOR JDTic Poisnel [69]
Salvinorin A >1000 5790 1.9 - agonist κOR NND Harding [70]
NOP-1A - - - 0.15 antagonist NOP FDPTP Pike [71]
MK-0911 94 - - 0.6 antagonist NOP SPB Hostetler [72]
EOP: Endogenous opioid peptide, EM: 4,5-Eopxy-morphinan, 4-AP: 4-Anilidopiperidine, orvinol: 6,14-
ethenomorphinan, Bentley-compound, ArAP: Arylacetamidopiperazine, APPB: Aryl-phenylpyrrolidinylmethyl-
phenoxy-benzamide, JDTic: trans-3,4-dimethyl-4-(3-hydroxyphenyl)- piperidine, NND: “non nitrogenous” diterpene,
FDPTP: 2′-fluoro-4′,5′-dihydrospiro[piperidine- 4,7′-thieno [2,3-c]pyran]- derivative, SPB: [[spiro[2.5]octan-8-
yl]-methyl]piperidin-4-yl] benzimidazol-2-one, a: in the rat brain b: in guinea pig brain membranes.
Luthra et al. [73] synthesized N17-cyclopropyl[11C]methyl-buprenorphine starting from
N17-nor-buprenorphine. Analogously to the N17-cyclopropyl[11C]methyl-diprenorphine synthesis [74]
the corresponding precursor, nor-BPN, was reacted with cyclopropyl[11C]carbonyl chloride and
the carbonyl functional group of the resulting intermediate was reduced with LiAlH4. Lever
et al. [75] developed a metabolically stable radiotracer, 6-O-(methyl-11C)-BPN, at Johns Hopkins
University in 1990 in a two-step synthesis from 3-O-TBDMS-6-O-desmethyl-BPN. The precursor
was selectively alkylated in position-6 with [11C]iodomethane/NaH in DMF at 80 ◦C for two min.
Following desilylation, [11C]BPN (14) was produced in 10% radiochemical yield with molar activity
of 41 GBq/µmol. Subsequently, Luthra et al. [76], aiming to avoid the formation of 3-O-alkylated
by-products, introduced the base-stable, acid labile trityl protecting group to protect the phenolic
hydroxyl in position-3. Applying 3-O-trityl-6-O-desmethyl-BPN in a two-step, fully-automated
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radiosynthesis (11C-methylation/deprotection), yielded [11C]BPN (14) in 15% radiochemical yield
and with a molar activity of 13-22 GBq/µmol. In 2014, Schoultz et al. [63] reported a procedure for
the radiosynthesis of 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-BPN ([18F]FE-BPN (19)) via 18F-fluoro-
alkylation of 3-O-trityl-6-O-desmethyl-BPN (TDBPN) precursor with [18F]fluoroethyl tosylate and
subsequent trityl deprotection. The decay corrected formulated product yield was 26 % and the molar
activity 50–300 GBq/µmol.
DPN, a semisynthetic thebaine/oripavine derivative with a methyl group amenable for labelling in
position-20, belongs structurally to the ring-C bridged morphinans (6,14-ethenomorphinans, orvinols,
Bentley-compounds) [48]. DPN is a nonselective OR antagonist with affinity in the nanomolar range
(Table 1), 100 times more potent than nalorphine. Indeed, DPN is used in the veterinary medicine
as an antidote/reversing agent/antagonist for remobilizing large African animals (rhinos/elephants,
Revivon®), which had been immobilized with the astonishingly potent agonists etorphine or carfentanil.
The first attempt at labelling of DPN with carbon-11 in postition-20 was reported by Burns et al. [77],
who usedN-cyclopropylmethyl-dihydronororvinone as precursor. The reaction of the precursor bearing
an acetyl group in position-7-alpha with [11C]methyllithium yielded 20-[11C]methyl-DPN ([11C]DPN
(15)). Luthra et al. [74] developed cyclopropyl[11C]methyl-DPN by alkylating N17-nor-DPN with
cyclopropane[11C]carbonyl chloride and then reducing the N-cyclopropyl[11C]carbonyl intermediate
with LiAlH4 in THF. The radiochemical yield of the corresponding radioligands were low in both
cases [74,77].
In 1987, Lever et al. [78] developed a [11C]DPN (15) synthesis by alkylating the precursor
3-O-TBDMS-6-O-desmethyl-DPN in position-6 with [11C]iodomethane in DMF containing sodium
hydride at 80 ◦C for two min. After cleavage of the TBDMS protecting group, [11C]DPN (15) was
obtained with 10 % radiochemical yield and 64 GBq/µmol molar activity. In 1994, Luthra and her
associates at the Hammersmith Hospital developed a new precursor for the radiosynthesis of [11C]DPN
(15) [76]. Selective alkylation of 3-O-trityl-6-O-desmethyl-DPN (TDDPN) with [11C]iodomethane
in the presence of NaH/DMF (95 ◦C, five min). Upon deprotection with 2 M hydrochloric acid (95
◦C, two min) the radiotracer 15 was obtained with a radiochemical yield of 13–19% and a molar
activity of 16–24 GBq/µmol. Recently, Fairclough et al. [79] at the University of Manchester reported a
modified synthetic method also starting from TDDPN, yielding [11]DPN (15) with ten times higher
molar activity (240 GBq/µmol) [76] and a radiochemical yield of 32%. The non-selective OR partial
mixed agonist/antagonist 6-O-(methyl-11C)-BPN ([11C]BPN, 14) accumulated in striatum, thalamus
and cingulate cortex in living baboon brain. Analysis of the dynamic PET data with a model assuming
irreversible trapping gave a net blood-brain clearance (Ki) of about 0.064 mL cm−3 min−1, which was
halved by administration of naloxone, indicating substantial displaceability [80]. In a study in heroin
addicts, the BPN occupancy at [11C]Caf (8) binding sites was estimated relative to the drug-free baseline.
An oral dose of 2 mg BPN had an occupancy of about 50% throughout brain, whereas 16 mg had 85%
global occupancy [81]. On the other hand, therapeutic methadone (18–90 mg/day) did not provoke
any discernible occupancy at 6-O-(methyl-11C)-diprenorphine ([11C]DPN, 15) binding sites, neither in
human opioid addicts, nor in mice, a phenomenon attributed to high agonist potency of methadone,
such that withdrawl effects are averted with a rather low occupancy [82]. In further preclinical studies
from the same research group, binding of [11C]DPN (15) in mouse brain was unaltered by treatment
with oxycodone (4) or morphine (1) (full agonists at µORs), but was reduced by approximately 90% by
BPN (partial agonist at µORs and antagonist at the δ- and κORs).
A comparative OR PET study in humans compared the distributions of the µOR-selective agonist
[11C]Caf (8) and the mixed antagonist [11C]DPN (15) [83]. Qualitatively, [11C]DPN (15) binding in
the striatum, cingulate and frontal cortex exceeded that of [11C]Caf (8) (which had highest binding
in the µOR-rich thalamus), consistent with labeling of additional non-µOR sites by [11C]DPN (15).
An investigation of ORs in human cerebellum showed abundant binding of a µOR-specific ligand in
the molecular layer, moderate binding of a κOR-selective ligand, but a near absence of δOR binding
sites, which was consistent with the observations of [11C]DPN (15) binding in vivo [84]. The presence
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of binding sites in cerebellum can be an obstacle to the valid use of reference tissue methods of
PET quantitation.
As a longer-lived alternative to [11C]DPN, (15), Wester et al. developed
6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-DPN ([18F]FE-DPN (16)) [85], which contains a 2-fluoroethoxy
group in position-6 instead of an OCH3. [18F]FE-DPN (16) was synthesized from TDDPN, the so
called “Luthra-precursor” [76], the same precursor as for [11C]DPN (15). For the synthesis of 16,
TDDPN was reacted with [18F]fluoroethyl tosylate ([18F]FE-Tos) in DMF in the presence of sodium
hydride for five min at 100 ◦C. The trityl protecting group was removed with 2 N hydrochloric
acid, yielding [18F]FE-DPN (16) with a radiochemical yield of 22 ± 7% and the molar activity was
37 GBq/µmol [85]. In 2013, Schoultz et al. [86] reported an automated radiosynthesis of 16 from
TDDPN with a decay-corrected radiochemical yield of 25 ± 7%. [18F]FE-DPN (16) has similar uptake as
[11C]DPN (15) in mouse brain, and obtained a BPND in human thalamus of about 2 relative to occipital
cortex, versus only 0.3 in somatosensory cortex [87]. Women showed faster plasma metabolism
[18F]FE-DPN (16) than men, which might contribute to apparent gender differences in binding [88].
The first instance of full compartmental analysis of an opioid PET ligand in living brain was for the
case of [11C]Caf, as described below. This fentanyl analogue belongs to the 4-anilidopiperidine (4AP)
class of OR ligands, which are potentµOR-selective agonists. Since 1960, numerous 4AP-type OR ligands
were synthesized and their structure-activity-relationship at ORs were recently summarized [89,90].
Caf is structurally different from fentanyl in that it contains an additional carboxymethyl group in
position-4 of the piperidine ring. Caf is a µOR-selective full agonist of extreme potency, being almost
10,000 times more potent than morphine (1) [58,91]. In 1985, [11C]Caf (8) radiotracer was applied in the
first human PET study [59,92]. For the radiosynthesis of [11C]Caf, desmethyl-Caf sodium carboxylate
was alkylated with [11C]iodomethane in DMF at 35 ◦C for five min [92]. This procedure gave molar
activity at the end of synthesis of 122 GBq/µmol, which would correspond to mass dose of about 500
pg in a human PET study, which is too low to have any effect on particpants. According to a novel
version of the radiosynthesis, desmethyl-Caf free acid serves as precursor in a reaction performed in
dimethylsulfoxide with [11C]methyl triflate in the presence of tetrabutylammonium hydroxide [93].
This procedure gave a molar activity of 5 GBq/µmol, which would correspond to a mass dose of 100 µg,
certainly intruding into the range causing some pharmacological effects. Risk of toxicity is a serious
matter in PET imaging with potent agonists, and for society in general, given the weaponization [94]
(figurative and literal) that is possible with Caf.
For the compartmental analysis of [11C]Caf (8), two models were fitted to dynamic time activity
curves (TACs) measured by PET in human brain relative to a metabolite-corrected arterial input
function [95]; this approach is the gold standard for PET quantitation. The input function obtained by
HPLC analysis of plasma extracts showed that untransformed parent fractions declined to 50% at 25
min post injection. The authors estimated microparameters for the reversible transfer of the tracer
across the blood-brain barrier (K1/k2), the reversible binding to a receptor compartment (k3/k4), and
the reversible association to a non-specific compartment in brain (k5/k6). The mean binding potential
(BP; k3/k4) was 1.8 in frontal cortex and 3.4 in thalamus at baseline, versus only 0.16 and 0.26 after
treatment with naloxone (0.1 mg/kg). This study set a very high standard for quantitative PET analysis,
although the molar activity of the tracer may not have been completely adequate. The amount of
mass injected corresponded to about 5 µg Caf per scan, which could cause some analgesia in humans,
although being less than 10% of the dose causing loss of consciousness. Nonetheless, this again raises
the issue of safety in PET studies with the using of high-potency full agonist ligands, as noted above.
Unless the the highest possible molar activity is obtained, pharmacologically significant occupancy can
occur, bringing a risk of toxicity. Test-retest studies with [11C]Caf (8) showed admirable low variability
(< 6%) and high intraclass correlation coefficients (ICC > 0.90) of the total distribution volume (VT)
relative to the metabolite-corrected arterial input, and likewise BPND relative to a reference tissue [96].
Phenethyl-orvinol (PEO) [97] shares the same in ring-C bridged morphinan scaffold as
DPN and BPN. PEO contains a 6,14-etheno-bridge, an N17-methyl substituent and a 2-phenethyl
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group in position-20. It is a full agonist with higher affinity at µOR (0.18 nM) and κORs
(0.12 nM) than to δORs (5.1 nM). The radiosynthesis of 6-O-(methyl-11C)-phenethyl-orvinol
([11C]PEO, 18) was reported by Marton et al. [62] in 2009. The Luthra-type trityl-protected
precursor (3-O-trityl-6-O-desmethyl-phenethyl-orvinol, TDPEO) was alkylated in position-6 with
[11C]iodomethane in the presence of 8-10 equiv. sodium hydride. The protecting group was removed
with 1 M hydrochloric acid in ethanol, yielding [11C]PEO (18) with a radiochemical yield of 57 ± 16%
and a molar activity of 60 GBq/µmol.
In 2012, Marton and Henriksen [98] reported the preliminary results of the synthesis
of 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-phenethyl-orvinol ([18F]FE-PEO, 17) starting from
6-O-(2-tosyloxyethyl)-6-O-desmethyl-phenylethyl-orvinol (TE-TDPEO) via direct nucleophilic
fluorination and subsequent deprotection. This procedure gave [18F]FE-PEO (17) in an isolated
preparative yield of 35 ± 8% with a molar activity of 55–130 GBq/µmol. In 2013, a research group
of the University of Cambridge [99] investigated [18F]FE-PEO (17) as a candidate OR PET-ligand,
obtained by an automated cGMP-compliant method the [18F]FE-PEO at 28 ± 15% yield and 52–224
GBq/µmol molar activity. In 2014, Schoultz et al. [63] reported the synthesis and biological evaluation
of three structurally-related 6-O-(2-[18F]fluoroethyl)-6-O-desmethy-orvinols, i.e. [18F]FE-DPN (16),
[18F]FE-BPN (19), and [18F]FE-PEO (17). The production of these 18F-fluoroethyl-orvinol radiotracers
(16,17,19) was accomplished from 3-O-trityl-6-O-desmethyl-orvinol precursors (TDDPN, TDBPN,
TDPEO) in a two-pot, three-step synthesis. [18F]FE-PEO (17) had a molar activity at end of synthesis
of 50–250 GBq/µmol [99], corresponding to an injected mass <1 µg in human PET studies. The total
distribution volume (VT) in rat brain ranged from 1 mL cm−3 in cerebellum to 8 mL cm−3 in thalamus;
displacement studies in vitro with the µOR-selective agonist DAMGO indicated high specificity in
certain brain regions. [18F]FE-DPN (16) had a molar activity of 37 GBq/µmol [85].
2.2. Delta Ligands
N1′-Methylnaltrindole (MeNTI, Figure 4) is a highly selective δOR antagonist (Table 1). MeNTI
was prepared from naltrexone (5) in a Fischer-indol synthesis with N-methyl-N-phenylhydrazine [64].
The radiosynthesis of [11C]MeNTI was reported by Lever et al. in 1995 [100]. In the first step,
3-O-benzyl-naltrindole was reacted with [11C]iodomethane in DMF in the presence of either sodium
hydride or tetrabutylammonium hydroxide at 80 ◦C for two min. The next step was hydrogenolysis of
the formed 3-O-benzyl-N1′-(methyl-11C)-naltrindole under heterogenous catalytic conditions (H2, 10%
Pd/C, DMF/ethanol, 80 ◦C, four min), or alternatively catalytic transfer hydrogenation (HCOONH4,
10% Pd/C, MeOH). This gave [11C]MeNTI (22) with 6% radiochemical yield and a molar activity of 76
GBq/µmol.
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Human PET studies with [11C]MeNTI (22) confirmed earlier demonstrations in living mice of
δOR-selectivity in vivo [101]. The binding ratio relative to cerebellum ranged from 1.1 in hippocampus
to 1.7 in striatum and insular cortex, regional values correlated rather precisely with known density
of δORs in vitro, and showed 50% displacement after administration of 50 mg NTX (5). The tracer
showed pseudo-irreversible binding characteristics over the course of 90 min, with net blood-brain
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clearance (Ki) ranging from 0.04 in cerebellum to 0.11 mL cm−3 min−1 in putamen [102]. The Ki for
[11C]MeNTI (22) in human brain declined by only about 20% after treatment with naloxone at a dose
completely displacing µOR sites [45]. The authors of that study suggested that incomplete and variable
δOR blockade might contribute to the success of NTX (5) as a treatment for alcoholism.
N1′-(2-[18F]fluoroethyl)naltrindole (23, [18F]FE-NTI, BU97001) was developed by Matthews et
al. in 1999 [103]. The precursor, N1′-[2-(tosyloxyethyl)]-3-O-benzyl-naltrindole, was prepared in
four consecutive transformations from naltrexone (5). In the first step, naltrexone (5) was reacted
in a Fischer-indol synthesis with 2-(N1-phenylhydrazino)acetic acid ethyl ester. The resulting
indolomorphinanyl-acetic ester was reacted with benzyl bromide to yield the 3-O-benzyl protected
NTI derivative, which was reduced with LiAlH4 in THF-toluene to afford the corresponding
indolomorphinanyl ethanol intermediate. This compound was reacted with tosyl chloride to
provide the appropriate precursor with a tosyloxy leaving group. For the radiosynthesis of
[18F]FE-NTI (23), the precursor was reacted in a direct nucleophilic reaction with potassium
[18F]fluoride/K2CO3/Kryptofix[2.2.2] in DMF to yield N1′-(2-[18F]fluoroethyl)-3-O-benzyl-naltrindole.
Final debenzylation by hydrogenolysis under heterogenous catalytical conditions (H2, Pd/C,
N,N-dimethyl formamide) gave [18F]FE-NTI (23) with a radiochemical yield of 10% and molar
activity of 31 GBq/µmol. [18F]FE-NTI (23) was an antagonist in mouse vas deferens with high selectivity
over µ- and κOR sites, and its tritiated version bound to rat whole brain as a single site with KD of 0.42
nM and Bmax of 3 pmol g−1 [104].
In 2007, Bourdier et al., [105] reported the radiosynthesis of a 2-[11C]methyl-
pyrrolo[3,4-b]pyridine-5,7-dione derivative (N-substituted-[11C]quinolinimide) (24). The radiotracer
containing a [11C]methyl-group on the pyridine ring was synthesized from a tributylstannyl precursor,
with introduction of the [11C]methyl group by the Stille reaction using [11C]iodomethane in the presence
of tris(dibenzylideneacetone)dipalladium, tri-o-tolylphosphine, K2CO3, and CuCl in DMF, heated at 90
◦C for five min. The labelled compound (24) was synthesized with a radiochemical yield of 60 ± 10%
and a molar activity of 30–56 GBq/µmol. The unlabelled version of the N-substituted quinolinimide
had higher δOR-selectivity than MeNTI, but its 11C-derivative (24) failed to label ORs in mouse brain,
due either to excessively rapid metabolism [105], or its only moderate affinity.
2.3. Kappa Ligands
GR89696 ((±)-methyl 4[(3,4-dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)- 1-piperazine-
carboxylate [106–108] (Glaxo Group Research Ltd.) is a κOR-selective agonist with an
arylacetamidopiperazine/diacylpiperazine structural core. GR103545, the biologically active
(R)-(−)-enantiomer of GR89696, displays subnanomolar affinity and 1000-fold selectivity for human
κOR (Ki = 0.02 nM), [65]. Ravert et al. [109] reported synthesis of both enantiomers of [11C]GR89696 (26,
Figure 5) from the corresponding chiral normethylcarbamoyl precursor [108,110]. The radiosynthesis
was accomplished by acylation of the secondary amine with [11C]methyl chloroformate in
dichloromethane in the presence of trimethylamine, giving product with molar radioactivity of
69 GBq/µmol. Mouse brain distribution of the synthesized enantiomers, ((R)-(−)-[11C]GR103545 (25)
and the (S)-(+)-enantiomer [11C]SGR) was determined in vivo, which showed the (S)-enantiomer
to be inactive. The low radiochemical yield of the radiosynthesis (2–14%) [110,111] motivated the
development of elaborate new radiochemical methods. In 2008, Schoultz et al. [112] developed a simple
[11C]methyl triflate mediated methylation of carbamino adducts. Normethylcarbamoyl-GR103545 was
converted to [11C]GR103545 (25) with [11C]CH3OTf under mild conditions in 64–91% radiochemical
yield. Wilson et al. [113] developed a method for preparing [11C-carbonyl]-methylcarbamates
directly from primary or secondary amines, applying either DBU or BEMP and cyclotron-produced
[11C]CO2. [11C-carbonyl]-GR103545 (25) was synthesized with high radiochemical purity (>98%) and
molar activity of 108–162 GBq/µmol. In 2011, Nabulsi et al. [114] reported an automated two-step,
one-pot procedure for the synthesis of [11C]GR103545 (25) from normethylcarbamoyl-GR103545 via
transcarboxylation using the zwitterionic carbamic complex DBU-CO2 and [11C]CH3OTf.
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In PET studies, the κOR-agonist ligand [11C]GR103545 (25) had a VT in baboon brain ranging 
from 3 mL cm−3 in cerebellum to 10 mL cm−3 in striatum and cingulate cortex [111]. Naloxone 
homogeneously displaced tracer throughout brain, but had no effect on VT in cerebellum, which 
would support use of that brain region as a reference tissue. The tracer had >100-fold selectivity for 
κ- over δ- and μORs in vitro [65]. Much as in baboons, PET studies in rhesus monkey showed VT 
ranging from 8 mL cm−3 in cerebellum to 21 mL cm−3 in striatum. Other monkey studies showed 
BPND ranging from 0.3 in amygdala to 2.2 in putamen [115]. This bolus plus infusion study with 
increasing mass dose in monkeys indicated an in vivo KD of 2 nM and Bmax of 1–6 pmol g−1. In 2014, 
Naganawa et al. [116] reported the first-in-human PET study with [11C]GR103545 (25). Test-retest 
variability of the quantitative endpoint VT was about 15%, and binding ranged from 8 mL cm−3 in 
cerebellum to 41 mL cm−3 in amygdala; Lassen plots with naltrexone blocking indicated a 
non-specific uptake (VND) of only 3.4 mL cm−3, thus emphasizing the absence of any non-binding 
reference region. 
Based on the substituted-diacylpiperazine scaffold of GR103545, researchers at Yale University 
developed the new κOR agonist radiotracers [11C]EKAP (27) [68] and [11C]FEKAP (28) [67] with 
improved pharmacological and PET-imaging profile compared with the native compound. In the 
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In PET studies, the κOR-agonist ligand [11C]G ( ) a T in bab on brain ranging
from 3 mL cm−3 in cerebellum to 10 mL cm−3 in striatu and cingulate cortex [111]. Naloxone
homogeneously displaced tracer throughout brain, but had no effect on VT in cerebellum, which would
support use of that brain region as a reference tissue. The tracer had >100-fold selectivity for κ- over δ-
and µORs in vitro [65]. Much as in baboons, PET studies in rhesus monkey showed VT ranging from
8 mL cm−3 in cerebellum to 21 mL cm−3 in striatum. Other monkey studies showed BPND ranging
from 0.3 in amygdala to 2.2 in putamen [115]. This bolus plus infusion study with increasing mass
dose in monkeys indicated an in vivo KD of 2 nM and Bmax of 1–6 pmol g−1. In 2014, Naganawa et
al. [116] reported the first-in-human PET study with [11C]GR103545 (25). Test-retest variability of the
quantitative endpoint VT was about 15%, and binding ranged from 8 mL cm−3 in cerebellum to 41 mL
cm−3 in amygdala; Lassen plots with naltrexone blocking indicated a non-specific uptake (VND) of
only 3.4 mL cm−3, thus emphasizing the absence of any non-binding reference region.
Based on the substituted- iacylpiperazine scaffol f 45, researchers at Yale University
developed the n w κOR agonist radiotracers [11C]E [11C]FEKAP (28) [67] with
improved pharmacological and PET-imaging profile co ative compound. In the
open-ring analogs of GR103545, the pyrrolidinyl-methyl group of the original molecule in position-3
was replaced by a diethylamino-methyl in EKAP and a ((ethyl)2-fluoroethyl)amino)methyl group in
FEKAP. Imaging studies [11C]EKAP (27) in rhesus monkey showed rapid metabolism in vivo and fast,
reversible binding kinetics in brain that was blockable with specific competitors. The BPND ranged
from 0.8 in frontal cortex to 1.8 in globus pallidus.
Researchers at Eli Lilly, in cooperation with the Yale University, developed κOR antagonist
radiotracers with the 3-pyridinyl-1-pyrrolidinylmethyl structural scaffold. Along these lines, in
2013, Zheng et al. [57] synthesized the selective κOR antagonist radiotracer [11C]LY2795050 (30)
from an iodophenyl precursor in a two-step procedure. The precursor was converted by transition
metal-mediated cyanation using H11CN and Pd2(dba)3/dppf to a [11C]nitrile intermediate. This latter
was partially hydrolysed with NaOH/H2O2 in DMF at 80 ◦C for five min, giving a 12% radiochemical
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yield with molar activity of 23.6 GBq/µmol. [11C]LY2459989 (31) was prepared in a two-step one-pot
radiosynthesis. In the first step, an aryl-iodide-type precursor was transformed in a palladium catalyzed
reaction (Pd2dba3/dppf) with H11CN to the corresponding [11C]nitrile, which was reacted with H2O2
under basic condition to afford 31 with 7.4% radiochemical yield and 23 GBq/µmol molar activity.
LY2459989 is the fluorine-containing analogue of LY2795050. Li et al. [117] synthesised the
18F-fluorine-labelled version of LY2459989 using two different methods. Using the nitro precursor, the
radiochemical yield was too low, but applying the iodonium ylide precursor, [18F]LY2459989 (30) was
prepared with 36% radiochemical yield and 1,175 GBq/µmol molar activity. While admirably high, this
molar activity falls far short of the theoretical maximium for 18F-, which is 63,000 GBq/µmol. Where
does all that non-radioactive fluoride come from?
As noted above, salvinorin A [118–120] is a naturally occurring non-alkaloid neo-clerodane
diterpenoid, isolated from Salvia divinorum. Also as noted above, smokings Salvinorin-A can provoke a
dissociative hallucinogenic experience distinct from that of the classical hallucinogens. It has a unique
structure with seven chiral carbons and is potent and highly selective κOR agonist; salvinorin A does
not display any significant activity at other OR subtypes. In 2008, Hooker et al. [121] synthesized the
carbon-11 labelled version of salvinorin A (33), using salvinorin B as precursor for the radiosynthesis.
The 2-alpha-hydroxyl group of the precursor was acylated with [11C]acetyl chloride in DMF in the
presence of DMAP at 0 ◦C for 7–10 min, giving a radiochemical yield of 3.5–10% with molar activity
7.4–28 GBq/µmol. PET studies in baboon brain showed rapid uptake and washout of [11C]salvinorin
A (33), matching the brief duration of the hallucinatory/dissociative experience reported by humans
users. Rat studies showed that acute doses of salvinorin A caused dose-dependent occupancy at brain
κORs labelled in vivo with [11C]GR103545 (25). Pretreatment with a high dose in the hours before PET
examination caused persistent reductions in receptor availability, despite the brief plasma half-life
of the drug, and despite the rather brief duration of the hallucinogenic experience. This suggests
that κOR activation by agonists such as salvinorin A provokes a delayed and persistent receptor
internalization [122].
In 2001, Thomas et al. [123] identified the first κOR-selective antagonist ligand,
trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine (JDTic, > 200-fold selective, Table 1), with non-opiate
structure. MeJDTic is a derivative of JDTic that is ring methylated on the nitrogen of the
tetrahydroisoquinoline. Poisnel et al. [69] prepared [11C]MeJDTic (29) from JDTic by methylation
with [11C]methyl triflate in acetonitrile at room temperature for three min. The radiochemical yield
was 78–98% and the molar activity 1.5–4.4 GBq/µmol. Recently, Schmitt et al. [124] synthesized
N-[18F]fluoropropyl-JDTic ([18F]FP-JDTic) (35)) from JDTic with [18F]fluoropropyl-tosylate in DMSO in
the presence of DIPEA and LiI at 150 ◦C for 30 min. In vivo studies in mouse showed accumulation of
[18F]FP-JDTic (35) in peripheral organs rich in κORs. [11C]MeJDTic (29) entered mouse brain in vivo,
albeit attaining a concentration of only 0.2–0.3% ID/g. Its binding was substantially reduced by
treatment with the κOR agonist U50,488, but was unaffected by morphine (1) or naltrindole (NTI), thus
attesting to its high selectivity for κOR sites [69]. The κOR-agonist [11C]LY2795050 (30) had an in vitro
binding affinity of 1 nM, and 25 fold selectivity over µORs (Table 1). It readily entered monkey brain,
and was substantially displacement by naloxone [57]. Displacement studies showed scant specific
binding in monkey cerebellum, which supports its use as a reference region for quantitation. The tracer
had a BPND as high as 1.0 in parts of the basal ganglia [125]. Dual tracer studies in monkey showed the
LY2795050 displaced [11C]Caf (8) from µOR sites with an ED50 of 119 µg/kg, whereas the ED50 at κOR
sites was 16 µg/kg, indicating 8-fold selectivity in vivo [125,126]. Corresponding human studies with
kinetic modelling showed VT ranging from 2 mL cm−3 in cerebellum to 4 mL cm−3 in amygdala, and
Lasson plots with partial NTX (5) blocking indicated a VND (non-specific binding) close to 1.6 mL cm−3,
thus giving a BPND of 1.5 in amygdala versus only 0.2 in cerebellum [126]. The test-retest reliability in
human brain was about 10% [127]. PET with [11C]LY2795050 (30) has revealed the dose-occupancy
relationship in human brain for the experimental κOR antagonist LY2456302 (34), which is under
development as a treatment of alcoholism [128].
Molecules 2019, 24, 4190 13 of 35
[11C]LY2459989 (31) had sub-nM affinity at κOR sites in vitro, with 30-fold selectivity over µOR
and 400-fold selectivity over δOR sites [66]. Preliminary PET studies in monkey showed rapid kinetics
and substantial displaceability in vivo, with BPND ranging from 0.5 in thalamus to 2.2 in globus pallidus.
A comparison of κOR ligands in rat showed that the agonist [11C]GR103545 (25) and the antagonist
[11C]LY2459989 (31) had similar displacement by various κOR antagonists. However, and of great
significance, the κOR agonists salvinorin A and U-50488, while displacing [11C]GR103545 (25) binding
in vivo, did not alter [11C]LY2459989 (31) binding [129], which may indicate an allosteric binding
mechanism. The novel κOR agonist tracer [11C]-EKAP (27) showed fast uptake kinetics and high
specific binding in monkey brain, with VT ranging from 12 mL cm−3 in cerebellum to mL cm−3 in
globus pallidus, corresponding to a BPND of 1.8, its binding was 95% displaced by pre-blocking with
the antagonists naloxone or LY2795050 [68].
The highly selective and potent κOR-ligand U-50488 served as a scaffold for developing
fluoro-alkylated PET ligands, but proved inappropriate due to 100-fold loss of affinity relative
to the starting compound [130]. The novel fluorinated κ-ligand [18F]LY2459989 (32) had similar kinetic
properties in monkey PET studies to those of [11C]LY2459989 (31) [117].
2.4. Nociceptin and Opioid-like 1 Receptors (ORL1)
Emerging evidence supports the use of agonists for the nociceptin/orphanin FQ peptide
receptor (NOP) in the clinical management of pain and for substance abuse [131], thus
presenting an attractive target for molecular imgaing A series of NOP ligands based on a
2′-fluoro-4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran]-scaffold were screened in rats [71].
Uptake in monkey brain in a baseline condition contrasted with a blocking condition
indicated specific binding of several of the [11C]-labelled compounds, of which [11C]NOP-1A
((2S)-2-[(2-fluorophenyl)methyl]- 3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran- 7,4′-piperidine-1′-
yl)-N-methyl-propanamide (36, Figure 6) was selected for further investigations. In the synthesis
developed by Pike et al. [71], [11C]NOP-1A (36) was prepared from a primary-amide type precursor
by methylation with [11C]iodomethane in DMSO basified with potassium hydroxide at 80 ◦C for 5
min. PET imaging experiments with 36 showed a VT in monkey brain ranging from 13 mL cm−3
in cerebellum to 21 mL cm−3 in amygdala. This fell globally to 8 mL cm−3 after blocking with the
antagonist SB-612111, indicating a BPND of 1–2 [132]. A somewhat lower VT range was detected in
human brain [133], where the test-retest reliability was about 12% [134].
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Figure 6. Chemical structures of selected ORL1 receptor ligands.
The NOP/ORL1 antagonist LY2940094 (37) exerted a dose-dependent reduction in immobility
in the forced swim test, matching that provoked by imipramine, consistent with a potential
antidepressant action [23]. Changes in [11C]NOP-1A (36) binding in brain of living rats revealed
the ORL1 occupancy of orally administered LY2940094 (37) [135]. MK-0911 (1-(2-fluoroethyl)-
3-[(3R,4R)-3-(hydroxymethyl)-1-[[(8S)-spiro[2.5]octan-8-yl]methyl]piperidin-4-yl]benzimidazol-2- one)
is a high affinity, selective NOP receptor antagonist developed by Merck Pharmaceuticals.
The fluorine-18 labelled version [18F]MK-0911 (39) had a VT in human brain ranging from 5 mL cm−3
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in cerebellum to 7 mL cm−3 in temporal cortex, with excellent test-retest stability [72]. Displacement
studies with antagonists revealed the presence of a small specific binding component in cerebellum,
again raising a red flag about reference tissue quantitation. Studies with the nociceptine ligand
[3H]PF-7191 (38) showed sub-nM binding displacement in vitro (Ki = 0.1 nM) and high selectivity over
other OR types, as well as promising displaceable binding in rat brain measured ex vivo [136].
3. Clinical Studies
3.1. Age and Gender
The BPND of [11C]Caf (8) relative to occipital cortex was 20% lower in thalamus and amygdala of
healthy, aged women compared with young women, but tended to increase with age in frontal cortex,
whereas increases were more consistently seen in aged men [137]. This finding seems relevant to the
age-dependent changes in sensitivity to µOR agonists, compounded by possible gender differences in
hepatic tracer metabolism, noted above. Preliminary results with [11C]LY2795050 (30) PET did not
indicate any change in κOR availability with age in humans [138]. Another κ-OR PET study with that
ligand showed slightly higher (5–10%) VT in widespread brain regions of male subjects than that seen
in age-matched women [139].
3.2. Epilepsy
A dual tracer PET study of patients with temporal lobe epilepsy showed increased binding of
[11C]Caf (8) to µORs in the temporal neocortex and decreased binding in the amygdala ipsilateral
to the epileptic focus [140]. However, binding of [11C]DPN (15) to µ- and other OR subtypes did
not differ between affected and unaffected cerebral hemipsheres, emphasizing the importance of
subtype selectivity in PET studies. Another multi-tracer PET study in temporal lobe epilepsy showed
increased µOR binding ([11C]Caf (8)) in medial inferior temporal cortex and a more widespread
increase in δOR binding ([11C]MeNTI (22)) in the affected temporal lobe [141]. Increased [11C]DPN (15)
binding in temporal pole and fusiform gyrus of epilepsy patients declined with time since last seizure,
indicating a transient response of the opioid system [142]. Applying a partial volume correction
revealed small post-ictal increases in [11C]DPN (15) VT in the (sclerotic) hippocampus relative to the
interictal state [143], possibly indicating reduced competition from endogenous opioids. Thus, there
may be reduced opioid transmission in the post-ictal period.
A study of five patients with reading epilepsy (i.e. seizures provoked by reading text) revealed
very circumscribed 10% reductions in [11C]DPN binding the temporal parietal cortex in the activation
condition compared to non-reading baseline, whereas no such changes was seen in control subjects [144].
In the context of a competition model, the authors interpreted this to indicate task-dependent release
of opioid peptides in the patients, but it is difficult to determine the causal relationship between this
release and the seizures.
3.3. Movement Disorders
In an MPTP model of acquired parkinsonism, a substantial striatal dopamine depletion to
FDOPA–PET was associated with a 20–30% reduction in the VT of [18F]FcyF, (11) in opioid-receptor
rich areas, i.e., caudate, anterior putamen, thalamus, and amygdala relative to intact animals [145].
These animals had recovery of their motor function, suggesting that the µOR changes were an adaptive
response to dopamine depletion. The same group reported that this effect was (paradoxically) bilateral
in animals with unilateral dopamine lesions [146]. In patients with Parkinson’s disease, the [11C]DPN
(15) binding relative to occipital cortex was 20–30% reduced in striatum and thalamus only in those
patients with iatrogenic DOPA-dyskinesia, but was unaffected in nondyskinetic Parkinson’s disease
patients [147]. This observation seems to merit further investigation, given the disabling effect of
dyskinesias often encountered in the treatment of Parkinson’s disease. On the other hand, there was no
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difference in [11C]DPN (15) binding in symptomatic DYT1 primary torsion dystonia patients relative
to controls [148].
Regional [11C]DPN (15) binding was unaffected in patients with restless legs syndrome (which,
like, Parkinson’s disease, is responsive to levodopa treatment). However, there was a negative
correlation between VT and motor symptom severity, and a negative correlation between severity of
pain and ligand binding in the medial pain system (medial thalamus, amygdala, caudate nucleus,
anterior cingulate gyrus, insular and orbitofrontal cortex). The authors interpreted this result in
relation to pain-induced release of endogenous peptides, rather than a primary aspect of restless legs
syndrome [149].
Binding of the non-selective OR ligand [11C]DPN PET was reduced by 31% in the caudate nucleus
and 26% in putamen of a small group of symptomatic Huntington’s disease patients compared to
age-matched healthy controls [150]. This effect was less pronounced than was the loss of dopamine
transporters seen in the same patients, suggesting that the reduction in ORs may partially accommodate
the nigrostriatal degeneration. Despite this finding, there has been no indication for opioid medications
in the symptomatic treatment of HD.
3.4. Pain
A qualitative study of post pontine infarct central pain showed a reduction in [11C]DPN (15) uptake
in the lateral cerebral cortex on the side contralateral to the main symptoms [151]. A more detailed
study indicated [11C]DPN (15) binding reductions in contralateral thalamus, parietal, secondary
somatosensory, insular and lateral prefrontal cortices; these reductions were similar irrespective of
the site of the lesion causing the central pain syndrome [152]. Indeed, this network of brain regions is
recognized as comprising a central pain pathway. Another [11C]DPN (15) study of central neuropathic
pain showed 15–30% lower OR-binding within the medial pain system (cingulate, insula and thalamus),
as well as the inferior parietal cortex of the lateral system (Brodman area 40). Patients with peripheral
neuropathic pain had bilateral and symmetrical decreases in [11C]DPN (15) binding in contrast to
the hemispheric changes seen in central pain patients [153]. As always, these binding reductions are
ambiguous, perhaps due to reduced receptor expression, increased occupancy, or internalization.
Poor sleep quality in relation to topical application of 10% capsaicin cream (which directly activates
cutaneous pain receptors) was associated with higher baseline [11C]Caf (8) BPND in the frontal lobe [154].
Thus, we suppose that baseline cortical binding may reflect a tradeoff between pain sensitivity and
some cognitive or resilience function subserved by µ-ORs. Capsaicin-induced pain provoked a decrease
in [11C]Caf (8) binding in the contralateral thalamus by as much as 50%, increasing as the subjective
severity of the pain [155]. Heat pain reduced the [18F]FE-DPN (16) binding in limbic and paralimbic
brain areas including the rostral ACC and insula [156]. Application of sustained painful stimulus of the
jaw muscle with saline injection provoked bilateral reductions in [11C]Caf (8) binding in the ipsilateral
amygdala (5%) and contralateral ventrolateral thalamus (7%) [157]. The same painful stimulus that
provoked 5–10% decreases in [11C]Caf (8) binding in healthy young men tended to increase binding in
women; this gender difference was most pronounced in the ventral striatum ipsilateral to the pain [158].
A small group of patients with trigeminal neuralgia had reduced [11C]Caf (8) binding in left nucleus
accumbens, a brain region earlier implicated in pain modulation and response to reward or aversive
stimuli [159]. It would be interesting to test if this phenomenon correlated with individual differences
in affective state or trait neuroticism.
In another [11C]Caf (8) study, the reduced binding provoked soon after administration of a
sustained pain of moderate intensity had normalized in the hours after cessation of the stimulus [160].
In general, painful stimuli do not desensitize with time, so the relationship between temporal dynamics
of opioid signaling and pain perception must be complex. Indeed, pain researchers and clinicians alike
are familiar with the phenomenon of allodynia, which is a decrease in pain threshold, or the conversion
of previously non-painful stimuli to pain. In a sciatic nerve stimulation model, pain conditioning some
hours after stimulation was associated with increased C-fibre response and reduced C-fibre threshold,
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as well as supraspinal changes marked by increased binding of [11C]PEO (18) in ipsilateral and bilateral
structures of the rat brain [161]. Thus, allodynia may indicate inactivation of pain-mediated opioid
release in brain, resulting in greater OR availability. On the other hand, an [18F]FE-DPN (16) PET
study in athletes contrasting receptor availability at rest with the condition immediately after running
a half marathon showed reduced binding in various paralimbic and prefontal cortical structures, to an
extent correlation with post-running euphoria (“runner’s high”) [162]. Similarly, a [11C]Caf (8) study
in recreationally active men showed a relationship between post-exercising euphoria with decreased
µOR binding in widespread cortical areas after high intensity exercise, although effects were less clear
after moderate intensity exercise [163].
Prolonged electrical stimulation of the motor cortex for relief of neuropathic pain caused reductions
in [11C]DPN (15) binding in part of the cingulate cortex, prefrontal cortex, the periaqueductal gray
prefrontal cortex, and cerebellum [164]. Some of these changes correlated with the extent of pain relief.
In a case study, a single session of motor cortex stimulation improved the cold pain threshold, while
decreasing [11C]Caf (8) binding in pain-network brain regions [165]. Other studies showed that low
cerebral binding of [11C]DPN (15) predicted for poor response to motor cortex stimulation for the
treatment of neuropathic pain [166]. Stimulation of the central grey for treatment of phantom limb
pain provoked a focal decrease in midbrain [11C]DPN (15) binding, indicating endogenous opioid
release [167].
Visceral pain applied by gastric inflammation was without effect on cerebral [11C]Caf (8) binding
in healthy volunteers [168], this standing in contrast to findings with somatic pain as described above.
On the other hand, vestibular stimulation provoked decreased [18F]FE-DPN (16) binding in parts of
the right dominant cortical vestibular network [169].
A [11C]Caf (8) study in which painful heat was applied after administration of supposedly
analgesic cream indicated a placebo-mediated reduction in receptor availability [170]. The same
group later showed that placebo transcranial direct current stimulation (tDCS) reduced [11C]Caf (8)
BPND in the periaqueductal gray matter (PAG), precuneus, and thalamus, indicating endogenous
opioid release [171]. This placebo effect apparently increased upon administration of verum tDCS.
In another study, acupuncture administered according to an authentic analgesic procedure had only
slight effects on the binding of [11C]DPN (15) in human brain [172]. However, a study with [11C]Caf
(8) showed acupuncture therapy to provoke short-term and persistent 10–30% increases in µOR
binding in pain-related brain regions; importantly the verum acupuncture condition was contrasted
with a sham acupuncture condition in that study [173]. Thus, while acupuncture analgesia may
be “in one’s head”, there seems to be a real component mediated by increased opioid transmission.
Transcutaneous electrical acupoint stimulation (TEAS) is an analogue of the electrical acupuncture
technique. Administration of TEAS at 2 Hz to anesthetized monkey provoked reductions in [11C]Caf
(8) binding in striatum, amygdala and ACC, whereas 100 Hz stimulation had no effect relative to
baseline PET recordings [174].
Reminiscent of the findings in the study of pain-induced sleep disturbance noted above, a
cross sectional study of sensory processing in healthy volunteers showed lower baseline binding
of [18F]FE-DPN (16) in regions such as insular cortex and orbitofrontal cortex of those with greater
sensitivity to cold pain. In addition, there were negative correlations between regional binding
and sensory thresholds for non-painful stimuli [175]. Similarly, the individual striatal binding of
[11C]Caf (8) BPND predicted cold pressor pain threshold, but not cold pressor pain tolerance or tactile
sensitivity [176]. A longitudinal [18F]FE-DPN (16) PET study in neuropathic pain model rats showed
lower µ+κ OR availability in the insula, caudate putamen, and motor cortex at three months after the
injury [177]. These reductions occurred in association with anhedonia (disinterest in sucrose solution).
Overall, these studies suggest that individual differences in OR signaling may mediate vulnerability to
environmental stressors, a topic to be elaborated in Section 3.5 below.
Binding of [11C]DPN (15) was reduced in pineal gland (but not in the brain per se) of patients who
had been experiencing cluster headache attacks [178], said to be one of the most painful experiences.
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The authors suggested that inputs from trigeminal nerve to the pineal gland might mediate this change.
A group of seven spontaneous migrainers showed ictal reductions in [11C]Caf (8) binding in the medial
prefrontal cortex, which correlated with the baseline or intra-ictal binding [179]. The [11C]DPN (15)
BPND in brain did not differ between migrainers and healthy controls, nor was there any effect of
placebo treatment in either group [180].
3.5. Personality, Drug Dependence, and Psychiatric Disorders
Scores in the personality trait of harm avoidance in a group of 23 healthy males correlated
positively with binding of [18F]FE-DPN (16) in the bilateral ventral striatum, suggesting a link with
predisposition to substance abuse [181]. It might follow that drug abuse is a kind of self-medication
for those with pronounced harm avoidance trait. A comparison of [11C]Caf (8) uptake in healthy
individuals showed that high scores in the harm avoidance trait were associated with high µOR
availability in frontal and insular cortex [182], again linking the hard avoidance trait with lower tonic
opioid transmission. Score in a scale of behavioral activation, which conceptually guides approach
behavior, and notably in a scale designated “fun-seeking”, correlated positively with [11C]Caf (8)
in widespread brain regions [183]. A [11C]Caf (8) study in 49 healthy volunteers showed an inverse
relationship between µOR availability in various brain regions and individual scores in the avoidance
dimension of interpersonal attachment [184]. Considering the harm avoidance findings, baseline µOR
availability may mediate a trade-off between harm avoidance and avoidant behavior in interpersonal
relationships, in a psychological analogue of pain or cold sensitivity.
In a large group of healthy women, [11C]Caf (8) binding had a negative correlation with BOLD
signal responses in amygdala, hippocampus, thalamus, and hypothalamus to viewing emotionally
arousing scenes [185]. Non-sexual, albeit pleasurable social touch from a partner provoked widespread
increases in [11C]Caf (8) binding, suggesting reduced opioid signaling [186], whereas social laughter
provoked by viewing comedic film clips decreased [11C]Caf (8) binding in thalamus, caudate nucleus,
and anterior insula. Furthermore, baseline µOR availability in some regions was associated with the
rate of social laughter [187]. These results are difficult to reconcile, since pleasurable social experiences
can seemingly have opposite effects on µOR availability. Contrasting the [11C]Caf (8) binding in
euthymic and unhappy states (provoked by autobiographical reflection) in young women showed
higher µOR availability in the rostral anterior cingulate, ventral pallidum, amygdala, and inferior
temporal cortex in the unhappy state [188]. This kind of sad reflection provoked greater increases in
[11C]Caf (8) binding in widespread brain regions of women with major depression [189], suggesting an
exaggerated opioid response in relation to mood disorder, as distinct from ordinary sadness. A pilot
PET study with the κOR-ligand [11C]GR103545 (25) did not reveal any binding differences between
healthy control and patients suffering from major depression [190]. However, a [11C]EKAP (27) κOR
study in healthy volunteers showed an inverse correlation between social status and [11C]salvinorin A
(33) binding in widespread brain areas, with a special association occurring in brain regions mediating
reward or aversion [191]. Given the association between social stress and depression, one might have
expected covariance κORs in the two studies.
A recent [11C]Caf (8) PET study of 19 schizophrenia patients and 20 controls showed a 10% lower
(Cohen’s d = 0.7) µOR -availability in striatium of the patient group. While such a decrease can hardly
be pathogonomic of disease, the authors also reported considerably higher inter-regional covariance
of the [11C]Caf (8) binding in the patients, which might indicate an aberent spatial pattern of opioid
signalling in schizophrenia [192]. There have been no OR PET studies in bipolar disorder.
A [11C]Caf (8) study showed that circulating levels of the anti-nociceptive cytokine IL-1ra (which
correlated with neuroticism scores) predicted for the pain response to a standard stimulus (saline
infusion to the masseter muscle), and likewise the reduction in µOR availability in the basal ganglia
during the painful stimulus [193]. In a group of female patients suffering from fibromyalgia, [11C]Caf
(8) binding correlated with pain-evoked BOLD signal changes in several brain regions, including
dorsolateral prefrontal cortex and nucleus accumbens [194]. Overall, these studies suggest some
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linking between opioid transmission, mood, and inflammatory markers, which returns to the the
notioin that OR signaling may mediate personality traits and vulnerability to stresses of various sorts.
[11C]Caf (8) PET showed persistently increased µOR binding in frontal and cingulate cortex of
acutely detoxified cocaine addicts, which correlated with the extent of craving [195]. Elevated [11C]Caf
(8) binding in frontal and temporal cortical regions was a significant predictor of time to relapse
to cocaine use among abstinent addicts [196]. Binge cocaine users showed a significant association
between [11C]GR103545 (25) binding to κORs with the amount of drug consumed. Furthermore, a
three-day cocaine binge reduced binding by about 15% [197]. The cerebral binding (VT) of the ORL1
ligand [11C]NOP-1A (36) was globally elevated 10% in detoxified cocaine users [198].
One [11C]Caf (8) PET study showed persistently increased µOR binding in striatum of detoxified
alcoholics, which furthermore correlated with the extent of craving [199]. Abstinent alcoholics showed
significantly higher [11C]Caf (8) binding compared to controls, but a blunting of the response to
amphetamine (which indirectly displaces µOR binding), resembling that seen by the same research
group in compulsive gamblers [200]. However, others saw only a small increase in [11C]DPN (15) VT
in brain of acutely withdrawn alcoholics, although there was a correlation between individual PET
results and craving scores at the time of scanning [201]; the combined (µ+κ) PET signal in that study
makes difficult a comparison with [11C]Caf (8) studies. Post mortem autoradiographic examination of
[3H]DAMGO binding in brain of a large group of alcoholics showed substantial reductions in µOR
binding sites, whereas low [11C]Caf (8) BPND in ventral striatum of acutely detoxified patients predicted
high risk of relapse and poor response to naloxone in interaction with the µOR rs1799971 allele [202].
The disagreement between µOR findings in vivo and post mortem could indicate low tonic occupancy in
alcohol dependent patients, since competition effects would disappear in autoradiographic studies.
In a [11C]MeNTI (22) PET study, there was globally 10–20% higher δOR binding in brain of a
large group of alcohol-dependent subjects; which reached significance upon correcting for age, gender,
and smoking status; there was an inverse relationship between binding in some regions and intensity
of craving [203]. The VT of the κOR-selective ligand [11C]LY2795050 (30) was significantly lower in
amygdala and pallidum of alcohol-dependent subjects [138]. This stands in contrast to the usual
finding of increased µOR binding and the single report of elevated δOR binding.
The naloxone challenge paradigm has a long history in investigations of the regulation of
the neuroendocrine axis, but it has been uncertain if naloxone-induced increases in ACTH and
cortisol secretion bear any relation to central OR pathways. In a [11C]Caf (8) PET study of healthy
volunteers there were negative relationships between cortisol (but not ACTH) response to naloxone
and ligand BPND in ventral striatum, putamen and caudate [204]. The inverse relationship between
naloxone-induced cortisol secretion and [11C]Caf (8) BPND in various brain regions of healthy volunteers
was absent in alcohol dependent subjects [205]. This suggests that central ORs exert a top-down
regulation of the neuroendocrine axis, which might contribute to individual differences in stress
response, and that the normal regulation of this axis is disprupted in alcohol dependence.
There was only a slight difference in [11C]Caf (8) binding between non-smoking carriers of the
µOR rs1799971 allelic variants, but this allelic difference was greater among smokers. Furthermore,
the contrast in PET results between active and denicotinized cigarette conditions revealed a positive
relationship between reward and altered µOR availability in the smokers [206]. An apparent
re-analysis of the same data showed widespread reductions in [11C]Caf (8) binding after smoking
a nicotine-containing cigarette; this effect was moderated by the rs1799971 polymorphism, where
carriers of the A allele showed greater response to active cigarette smoking, and higher baseline
µOR binding [207]. The authors conceded that non-nicotinergic factors, i.e. conditioning, could be
contributing to aspects of smoking related opioid transmission [208].
Smoking subjects with higher dependence, craving, and cigarette consumption rates showed
lower baseline [11C]Caf (8) BPND in limbic brain regions. There was bluniting of this association during
NTX (5) treatment [209], but there was very low residual specific binding in the NTX condition, which
must have compromised the sensitivity of the method. Another [11C]Caf (8) PET study showed no
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difference in BPND between placebo and active nicotine cigarette conditions, and no difference between
smokers and nonsmokers. However, there was a negative correlation in the smokers between BPND in
bilateral superior temporal cortex with scores in an index of nicotine dependence [210].
As noted above, challenge with amphetamine can indirectly provoke increased opioid peptide
release. However, in a placebo-controlled, double-blinded and randomized [11C]Caf (8) PET study,
amphetamine challenge (0.3 mg/kg) did not alter µOR availability in healthy male volunteers [211].
This stands in contrast to another study, wherein a high dose of amphetamine (0.5 mg/kg) provoked
reductions in [11C]Caf (8) binding in widespread brain regions, i.e. frontal cortex, putamen, caudate,
thalamus, anterior cingulate, and insula, whereas a sub-pharmacological dose was without such
an effect [212,213]. Preclinical studies point to the importance of receptor internalization on the
vulnerability of OR-receptor binding to challenge with amphetamine [214]. Notwithstanding this
caveat, amphetamine induced reductions in [11C]Caf (8) binding were blunted in compulsive gamblers
compared to that in a healthy control group controlled for smoking and drinking [215]. There was a
general correlation between dopamine synthesis capacity to FDOPA PET and [11C]Caf (8) binding in
putamen of healthy controls, and likewise in pathological gamblers, consistent with a tight relationship
between dopamine and opioid systems in relation to compulsive behaviors [216].
Women with bulimia nervosa had reduced [11C]Caf (8) binding in the left insula, to an extent
correlating with their duration of fasting [217]. Obese patients (BMI 40) had globally 20% lower
[11C]Caf (8) BPND compared to lean volunteers; contrary to some reports, the same obese subjects had
normal dopamine D2 receptor levels in striatum [218]. There were similar reductions in [11C]Caf (8)
binding in morbidly obese subjects and patients with binge eating disorder [219]. Weight loss after
bariatric surgery for the treatment of obesity resulted in a global 25% increase of µOR binding [220].
A dual tracer study with [11C]Caf (8) and the dopamine receptor ligand [11C]raclopride showed a
high correlation in the striatum of lean subjects, whereas this correlation was considerably weaker in
the ventral (limbic) striatum of the morbidly obese, suggesting an uncoupling of opioid/dopamine
interactions in that condition [221]. This finding might predict analogous results in gambling and
substance abuse disorders, which likewise may involve dysregulation opioid/dopamine interactions.
Feeding, regardless of the hedonic experience (palatable versus unpalatable meal), provoked
widespread decreases in [11C]Caf (8) binding in non-obese healthy subjects, suggesting that OR
transmission mediates some aspect of the rewarding properties of food [222]. Also in non-obese
subjects, [11C]Caf (8) BPND in amygdala correlated inversely with BMI in the range 20–27 [223]. In that
study, BPND in other brain regions correlated with the BOLD signal response in orbitofrontal cortex
upon viewing palatable food. In a group of lean subjects, the [11C]Caf (8) BPND at baseline in widespread
brain regions correlated with BOLD responses to viewing palatable food [224], suggesting that low
basal occupancy increases the response to cues. Interestingly, exercise increased or decreased thalamic
µOR binding in these subjects; the direction of this change correlated with the individual BOLD signal
in the contrast between viewing palatable and non-palatable food. This draws attention to individual
differences in effects of exercise on the hedonic response to food, which may have some bearing on
the relationship between exercise and weight loss, with the caveat that only intense exercise may
significantly engage opioid transmission, as claimed above. Other studies show widespread reductions
in µOR availability in frontolimbic regions after high intensity aerobic exercise, in correlation with
negative affect. In contrast, mean binding was unaltered after moderate-intensity exercise, although
there was some positive association with euphoria [225]; too much of a good thing spoils runner’s
high, it seems.
4. Conclusions and Outlook
The past decades have seen extraordinary progress in the development of ligands for PET studies
of ORs. Early radiopharmaceutical research focused on studies with the antagonist [11C]DPN (15)
and the µOR-selective agonist [11C]Caf (8), and the great preponderance of human PET studies
have employed these and closely related tracers. While studies with non-selective tracers reveal the
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composite of OR binding sites, specific tracers may be more indicative of physiological changes in
disease states. Attaining high molar activity is of great importance in PET studies with [11C]Caf (8)
and other highly potent agonist ligands; fortunately, most tracers described in this review have molar
activities of at least 50 GBq/µmol, corresponding to an injected mass of about 1 µg of the drug. This is
hardly a relevant dose in the case of antagonist ligands, and would give a comfortable 100-fold margin
of safety with the potent µOR agonist [11C]Caf (8).
The µOR ligands have the useful property of binding in competition with endogenous opioid
peptides, such that changes in the uptake in PET studies can reveal altered endogenous opioid release
under various physiological conditions. This model has been particularly useful in studies of pain
pathways, which largely involve µORs in telencephalon, and in some pharmacological or behavioral
activation studies. However, the simple competition model may be inadequate to account for all
observations. Thus, one of the [11C]Caf (8) studies noted above reports widespread reductions in µOR
availability after smoking [207], despite the 30–3000-fold lower affinity of endogenous opioid peptides
at µOR. This would seem to imply an implausibly enormous increase in peptide release to effect such
changes by competition alone.
Pain studies have so far dominated the field of clinical PET research with OR-ligands, with
relatively few reports on other models or conditions, as summarized in Table 2. For example, there in
only one PET study of opioid receptors in schizophrenia, and only scant documentation in depression,
or for that matter, in a range of common neurological disorders. In several human diseases noted
above, the OR binding may be only 10% higher or lower than in the control group; while these small
differences can have a large effect size, it is perhaps difficult to argue that such small differences can be
causative of complex disorders or symptoms.
Table 2. A summary of the key results with opioid PET in clinical research.
Condition Ligand Main Finding Ref.
Healthy aging [
11C]Caf (8)
(µOR)
20% decrease in frontal cortex (females) [137]
Epilepsy [
11C]Caf (8)
(µOR)
Increased in ipsilateral temporal lobe, decreased in amygdala [140]
Epilepsy [
11C]DPN (15)
(mixed ligand)
No change [140]
Parkinson’s disease [
11C]DPN (15)
(mixed ligand)
20–30% decrease in striatum and thalamus only in those
patients with iatrogenic DOPA-dyskinesia [147]
Huntington’s disease [
11C]DPN (15)
(mixed ligand)
30% reduced in caudate/putamen [150]
Pontine infarct central pain [
11C]DPN (15)
(mixed ligand)
Reduced throughout pain network [151]
Capsaicin-induced acute pain [
11C]Caf (8)
(µOR)
Up to 50% decrease contralateral thalamus, in proportion to
subjective severity [155]
Sustained painful stimulus of the jaw
muscle with saline injection
[11C]Caf (8)
(µOR)
Blateral decrease in binding in the ipsilateral amygdala (5%)
and contralateral ventro-lateral thalamus (7%) [157]
painful heat [
11C]Caf (8)
(µOR)
Placebo effect on binding changes [170]
Acupuncture therapy with sham
acupuncture control
[11C]Caf (8)
(µOR)
Persistent 10–30% increases in µ-OR binding in pain-related
brain regions [173]
Harm avoidance trait in healthy males [
18F]FE-DPN (16) (mixed
ligand)
Trait correlated positively with binding in vental striatum,
suggesting link with substance abuse [181]
Correlation with BOLD signal responses
A large group of healthy women, binding.
to viewing emotionally arousing scenes
[11C]Caf (8)
(µOR)
Negative correlation in amygdala, hippocampus, thalamus,
and hypothalamus [185]
Major depressive disorder [
11C]GR103545 (25)
(κOR)
No difference from controls [190]
Detoxified cocaine addicts [11C]Caf (8) (µOR)
Increased in frontal and cingulate cortex, which correlated
with the extent of craving [195]
Detoxified alcohol-dependent subjects [11C]MeNTI (22) (δOR)
Globally 10–20% increased binding inverse relationship in
some regions with intensity of craving [203]
Obesity (BMI > 40) [
11C]Caf (8)
(µOR)
Globally 20% lower compared to lean volunteers [218]
Feeding, regardless of the hedonic
experience in non-obese subjects
[11C]Caf (8)
(µOR)
Widespread decreases in binding [222]
Addiction research using PET studies of ORs are so far mostly confined to alcohol, cocaine, and
nicotine abuse and (strangely, perhaps), opioid addiction has hardly been a research theme, other than in
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a few occupancy studies. Since antagonists are relatively safe at doses provoking high occupancy (viz 50
mg naloxone for opioid overdose), we suppose that the Bmax of ORs might be determinable in relation to
opioid addiction and withdrawal by conducting serial PET studies over a range of molar activity, even in
the presence of significant agonist occupancy. Indeed, chronic morphine was reported 45 years ago to
increase the abundance of [3H]naloxone binding sites in rat brain [226], but no such studies are reported
in human opioid users, despite the catastrophe of the current opioid addiction epidemic. This kind of
information might help to understand better the correlates of addiction and relapse. In addition, genetic
studies of dopaminergic and opioid systems in relation to addiction [227], in conjunction with molecular
imaging studies, could help to establish better the risk factors for opioid addiction. Endomorphins
and other novel opioid petpides may present new avenues for obtaining opioid analgesia [228], while
moderating the risk of “iatrogenic opioid addiction”. The development of PET tracers with good binding
properties in vivo and high selectivity for ORs other than the µ-type has accelerated in the past decade.
However, there remain relatively few clinical molecular imaging studies of these important targets. Thus,
developments in radioligand chemistry have for the presence to read for the present presence outpaced
clinical PET imaging, a state of affairs that could enable and motivate a broad range of studies focusing on
non-µORs over the coming decades. Just for example, κORs have an established role in the reinstatement
of stress induced drug use in experimental animals, i.e. nicotine use [229], and very recent results indicate
a relationship between κORs and stress-induced binge cocaine use [197].
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
Compound Name, Synonyms
3-O-Ac-[18F]FcyF (10) 3-O-[18F]acetylcyclofoxy, 3-O-Acetyl-6-deoxy-6-beta-[18F]fluoronaltrexone
β-Endorphin
Tyr-Gly-Gly-Phe-Met-Thr-Ser-Glu-Lys-Ser-Gln-Thr-Pro-Leu-Val-
Thr-Leu-Phe-Lys-Asn-Ala-Ile-Ile-Lys-Asn-Ala-Tyr-Lys-Lys-Gly-Glu
CAS RN: [61214-51-5]
BEMP
2-tert-butylimino-2-diethylamino-1,3-dimethyl-perhydro-1,3,2-diazaphosphorine
CAS RN: [98015-45-3]
[11C]BPN (14) [11C]buprenorphine, [6-O-methyl-11C]buprenorphine
Caf
carfentanil, 1-(2-phenylethyl)-4-[(1-oxopropyl)phenylamino]-4-piperidine
carboxylic acid methyl ester, R-31,833, 4-carboxymethyl-fentanyl,
CAS RN: [59708-52-09]
[11C]Caf (8) [11C]carfentanil
[3H]DAMGO [3,5-3H]Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene, CAS RN: [6674-22-2]
DIPEA ethyldiisopropylamine, N,N-diisopropylamine, Hünig’s base
DMF N,N-dimethylformamide
[11C]DPN (15) [11C]diprenorphine, [6-O-methyl-11C]diprenorphine
dppf 1,1’-ferrocenediyl-bis(diphenylphosphine), CAS RN: [121450-46-8]
Dynorphin A [1-17] Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-T rp-Asp-Asn-Gln CAS RN: [80448-90-4]
Dynorphin A [1-8] Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile, CAS RN: [75790-53-3]
Dynorpin B [1-13]
Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Gln-Phe-Lys-Val-Val-Thr,
CAS RN: [83335-41-5]
[11C]EKAP (27) (R)-(methyl-11C) 4-(2-(3,4-dichlorophenyl)acetyl)-3-((diethylamino)methyl) piperazine-1-carboxylate
cyF
cyclofoxy, 6-deoxy-6β-[18F]fluoro-naltrexone,
N-cyclopropylmethyl-6-deoxy-6β-fluoro-noroxymorphone,
17-cyclopropylmethyl-4,5α-epoxy-6β-fluoro-morphinan-3,14-diol
CAS RN: [103223-57-0]
[18F]FcyF (11)
[18F]cyclofoxy, 6-Deoxy-6-β-[18F]fluoro-naltrexone,
N-cyclopropylmethyl-6-deoxy-6β-[18F]fluoro-noroxymorphone,
CAS RN: [103223-58-1]
FDOPA 6-fluoro-L-dopa, 2-Fluoro-5-hydroxy-L-tyrosine, CAS RN: [144334-59-8]
[18F]FE-DPN (16) 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-diprenorphine
[11C]FEKAP (28) (R)-(methyl-11C)4-(2-(3,4-dichlorophenyl)acetyl)-3-((ethyl(2-fluoroethyl)amino) methyl)piperazine-1-carboxylate
[18F]FE-BPN (19) 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-buprenorphine
[18F]FP-norBPN (21) N17-(3-[18F]fluoropropyl)-nor-buprenorphine
[18F]FP-norDPN (20) N17-(3-[18F]fluoropropyl)-nor-diprenorphine
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[18F]FE-NTI (23) [18F]fluoroethyl-naltrindole, N1’-(2-[18F]Fluoroethyl)-naltrindole, [18F]BU97001
[18F]FE-PEO (17) 6-O-(2-[18F]fluoroethyl)-6-O-desmethyl-phenethyl-orvinol
[18F]FE-Tos [18F]fluoroethyl tosylate
Foxy
6-deoxy-6β-fluoro-oxymorphone, «fluorooxymorphone », 4,5α-Epoxy -6β-fluoro-17-methyl-morphinan-3,14-diol,
CAS RN: [92593-44-7]
[3H]Foxy
[1,2-3H]-4,5α-epoxy-6β-fluoro-17-methyl-morphinan-3,14-diol,
CAS RN: [96917-45-2]
[11C]GR103545 (25) [(3,4-dichlorophenyl)acetyl]-(3R)-(1-pyrrolidinylmethyl)-1-piperazine carboxylic acid methyl-11C ester
[11C]GR89696 (26) 4-[(3,4-dichlorophenyl)acetyl]-3-(R,S)-(1-pyrrolidinylmethyl)-1-piperazine carboxylic acid methyl-11C ester
HD Huntington’s disease
[11C]LAAM (13)
N-(methyl-11C)-L-α-acetoxymethadol, N-(methyl-11C)-levo-alpha-acetyl methadol, N-(methyl-11C)-levomethadyl
acetate
Leu5-enkephalin H-Tyr-Gly-Gly-Phe-Leu-OH, CAS RN: [58569-55-4]
LY2459989 3-fluoro-4-[4-[[(2S)-2-(3-pyridyl)pyrrolidin-1-yl]methyl]phenoxy] benzamide
LY2795050
3-chloro-4-[4-[[(2S)-2-(3-pyridyl)pyrrolidin-1-yl]methyl]phenoxy] benzamide,
CAS RN: [1346133-08-1]
LY2456302 (34)
(S)-4-(4-((2-(3,5-dimethylphenyl)pyrrolidin-1-yl)methyl)phenoxy)- 3-fluorobenzamide, CERC-501, CAS RN:
[1174130-61-0]
LY2940094
([2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4′-piperidine]-
1′-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol), BTRX-246040,
CAS RN: [1307245-86-0]
Met5-enkephalin H-Tyr-Gly-Gly-Phe-Met-OH
[11C]MeJDTic (29)
(3S)-7-hydroxy-N-((1S)-1-[[3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-
1-piperidinyl]methyl]-2-methylpropyl)-2-[11C]methyl-1,2,3,4-tetrahydro-
3-isoquinolinecarboxamide
[11C]MeNTI (22) [11C]methyl-naltrindole, N1’-[11C]methyl-naltrindole
[18F]MK-0911 (39)
1-(2-[18F]fluoroethyl)-3-[(3R,4R)-3-(hydroxymethyl)-1-[[(8S)-spiro[2.5]octan-8-yl]
methyl]piperidin-4-yl]benzimidazol-2-one
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, CAS RN: [28289-54-5]
Oxycodone 14-hydroxy-dihydrocodeinone, CAS RN: [76-42-6]
Naloxone
N17-allyl-14-hydroxy-dihydromorphinone, N17-Allyl-noroxymorphone,
CAS RN: [465-65-6]
Naltrexone
N17-cyclopropylmethyl-14-hydroxy-dihydromorphinone,
N17-cyclopropylmethyl-noroxymorphone, NTX
CAS RN: [16590-41-3]
Nociceptine Phe-Gly-Gly-Phe-Thr-Gly-Ala-Arg-Lys-Ser-Ala-Arg-Lys-Leu-Ala-Asn-Gln
N-substituted-
[11C]quinolinimide (24)
6-(2-{2-[4-(4-fluorobutyl)-benzenesulfonyl]-1,2,3,4-tetrahydro-isoquinolin-1-yl}
-ethyl)-2-[11C]methyl-pyrrolo[3,4-b]pyridine-5,7-dione
NTI naltrexone-indole, naltrindole, CAS RN: [111555-53-4]
[11C]NOP-1A (36)
(2S)-2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydro-thieno[2,3-c]pyran-
7,4'-piperidine]-1'-yl)-N-[11C]methyl-propanamide
OR opioid receptor
[11C]PEO (18) [11C]phenethyl-orvinol, [6-O-methyl-11C]phenethyl-orvinol
PET positron emission tomography
Pd2dba3 Pd2(dba)3, tris(dibenzylideneacetone)dipalladium, CAS RN: [51364-51-3]
[3H]PL017
[3,5-3H]Tyr-Pro-(NMe)Phe-d-Pro-NH2, 3-N-Me-Phe-[3H]morphiceptin,
[3H] [MePhe3,D-Pro4]morphiceptin
Salvinorin A
methyl (2S,4aR,6aR,7R,9S,10aS,10bR)-9-acetyloxy-2-(furan-3-yl)-6a,10b-dimethyl-
4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate, CAS RN: [83729-01-5]
TBDMS tert-butyldimethylsilyl protecting group
TDBPN 3-O-trityl-6-O-desmethyl-buprenorphine, CAS RN: [157891-93-5]
TDDPN
3-O-trityl-6-O-desmethyl-diprenorphine, CAS RN: [157891-92-4],
“Luthra-precursor”, TDDPN was the first product of the company ABX advanced biochemical compounds
Biomedizinische Forschungsreagenzien GmbH, Radeberg in 1997
TDPEO 3-O-trityl-6-O-desmethyl-phenethyl-orvionol, CAS RN: [1187551-69-4]
U-50488
3,4-dichloro-N-methyl-N-[(1R,2R)-2-(1-pyrrolidinyl)cyclohexyl]- benzene acetamide, NIH10533, CAS RN:
[67198-13-4]
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